Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 30, 2015 6:40 PM ET


Company Overview of Carmot Therapeutics, Inc.

Company Overview

Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California.

409 Illinois Streeet

San Francisco, CA 94158

United States

Founded in 2008



Key Executives for Carmot Therapeutics, Inc.

Co-Founder and Chief Executive Officer
Vice President of Business Development
Compensation as of Fiscal Year 2014.

Carmot Therapeutics, Inc. Key Developments

Carmot Therapeutics, Inc. Presents at BIO International Convention, Jun-26-2014 10:00 AM

Carmot Therapeutics, Inc. Presents at BIO International Convention, Jun-26-2014 10:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Carmot Therapeutics Names Dave Jobes, PhD as Vice President of Business Development

Carmot Therapeutics reported that Dave Jobes, PhD, has joined the company as vice president of business development. Jobes brings nearly 15 years of biopharmaceutical industry experience to Carmot from such diverse areas as diagnostics, vaccines, and small molecule therapeutics. Prior to joining Carmot, Jobes headed his own consulting firm focused on assisting clients with transactional work and business development strategies. Previously, he was co-founder and vice president of business development at Presidio Pharmaceuticals. Jobes will be leading the company's partnering efforts around its internal programs in diabetes and cancer, its proprietary lead-identification technology, Chemotype Evolution, and Tethering, to which Carmot has an exclusive license.

Carmot Therapeutics, Inc. Enters into Collaboration and License Agreement with Amgen Inc

Carmot Therapeutics, Inc. has entered into a collaboration and license agreement with Amgen, Inc. During the collaboration Carmot will apply its proprietary Chemotype Evolution to discover novel drug leads for two targets selected by Amgen. Carmot and Amgen will work together to identify and optimize drug candidates, while Amgen will be solely responsible for their clinical development. Under the terms of the agreement, Carmot will receive an upfront payment, research funding, and preclinical and clinical milestone payments. In addition, a royalty will be paid on commercial sales of products emerging from the collaboration.

Similar Private Companies By Industry

Company Name Region
VGX Animal Health, Inc. United States
KI NutriCare, Inc. United States
Summers Laboratories Incorporated United States
Lyric Pharmaceuticals, Inc. United States
Larasan Pharmaceutical Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Carmot Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at